Modified Nucleosides “(ProTide)” as Potential Anti-HCV Therapeutics

Authors

  • N.A. Elsharif Department of Chemistry, Faculty of Science, University of Benghazi, Benghazi, Libya
  • O. Dakeel Department of Chemistry, Faculty of Science, University of Benghazi, Benghazi, Libya

DOI:

https://doi.org/10.37591/(rrjops).v8i1.484

Abstract

Hepatitis C virus (HCV) is among the most common causes of cirrhosis and chronic liver disease worldwide. As a result, many researchers are interested in designing and synthesis of a clinical treatment for HCV. Nucleoside monophosphates and monophosphonates play such an important role for treatments of incurable diseases such as hepatitis. For example, 2'-C-methyladenosine and 2'-C-methyl guanosine have shown activities against HCV in the replicon assay as well as against several members of the flavivirus family. However, their development as drug molecules has been hindered by the inherent poor drug-like properties of the monophosphate and monophosphonate groups. These groups have low bioavailability due to the inefficient cellular uptake, poor in vivo stability and poor intracellular metabolism; the latter drawback being most relevant to monophosphates than monophosphonates. These limitations can be addressed by using por Tide strategy, which is able to help the nucleoside monophosphate delivered inside the cell. In this review, we have discussed the different keys monophosphate and monophosphonate nucleoside prodrugs that has entered clinical development. In addition, the role of the ProTide technology is highlighted for the success in the discovery of nucleoside therapeutics.

 

Keywords: Hepatitis C, antiviral, nucleoside, ProTide, monophosphates

Cite this Article

Elsharif NA, Dakeel O. Review Article about Modified Nucleosides "(ProTide)" as Potential Anti-HCV Therapeutics. Research and Reviews: A Journal of Pharmaceutical Science. 2017; 8(1): 32–39p.

Downloads

Published

2019-06-19

Issue

Vol. 8 No. 1 (2017)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.